<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: investment", fill: "#008b8b"},
{source: "1: investment", target: "1: common stock involves", fill: "#008b8b"},
{source: "1: investment", target: "2: should carefully", fill: "#00bfff"},
{source: "2: should carefully", target: "2: following risk factors together", fill: "#00bfff"},
{source: "2: following risk factors together", target: "2: Annual Report ", fill: "#00bfff"},
{source: "2: Annual Report ", target: "2: raise additional capital", fill: "#00bfff"},
{source: "2: raise additional capital", target: "2: development programs", fill: "#00bfff"},
{source: "2: should carefully", target: "5: sustain operations", fill: "#c46210"},
{source: "5: sustain operations", target: "5: development goals at least", fill: "#c46210"},
{source: "5: sustain operations", target: "7: raise additional", fill: "#004953"},
{source: "7: raise additional", target: "7: development activities", fill: "#004953"},
{source: "7: development activities", target: "7: proposed products", fill: "#004953"},
{source: "7: raise additional", target: "10: delay scale back", fill: "#f7e98e"},
{source: "10: delay scale back", target: "10: eliminate research", fill: "#f7e98e"},
{source: "10: eliminate research", target: "10: enter into collaborations", fill: "#f7e98e"},
{source: "10: enter into collaborations", target: "10: with third parties", fill: "#f7e98e"},
{source: "10: with third parties", target: "10: commercialize potential products", fill: "#f7e98e"},
{source: "10: commercialize potential products", target: "10: technologies", fill: "#f7e98e"},
{source: "10: technologies", target: "10: might otherwise seek", fill: "#f7e98e"},
{source: "10: might otherwise seek", target: "10: commercialize ourselves", fill: "#f7e98e"},
{source: "10: commercialize ourselves", target: "10: arrangements", fill: "#f7e98e"},
{source: "10: delay scale back", target: "12: convertible into equity", fill: "#e9d66b"},
{source: "12: convertible into equity", target: "12: issuance may", fill: "#e9d66b"},
{source: "12: issuance may", target: "12: ownership dilution", fill: "#e9d66b"},
{source: "12: ownership dilution", target: "12: stockholders", fill: "#e9d66b"},
{source: "12: stockholders", target: "12: price may decline", fill: "#e9d66b"},
{source: "12: convertible into equity", target: "19: development", fill: "#30ba8f"},
{source: "19: development", target: "19: candidates", fill: "#30ba8f"},
{source: "19: development", target: "29: substantially", fill: "#db7093"},
{source: "29: substantially", target: "29: potential products", fill: "#db7093"},
{source: "29: potential products", target: "29: research preclinical development", fill: "#db7093"},
{source: "29: research preclinical development", target: "29: clinical testing revenues from sales", fill: "#db7093"},
{source: "29: clinical testing revenues from sales", target: "29: products will", fill: "#db7093"},
{source: "29: products will", target: "29: next several years", fill: "#db7093"},
{source: "29: substantially", target: "31: commercially introduce", fill: "#ffdab9"},
{source: "31: commercially introduce", target: "31: will likely", fill: "#ffdab9"},
{source: "31: will likely", target: "31: significant amount", fill: "#ffdab9"},
{source: "31: significant amount", target: "31: preclinical testing", fill: "#ffdab9"},
{source: "31: preclinical testing", target: "31: clinical trials", fill: "#ffdab9"},
{source: "31: commercially introduce", target: "49: delays could", fill: "#c2b280"},
{source: "49: delays could", target: "49: increased costs delays", fill: "#c2b280"},
{source: "49: increased costs delays", target: "49: product development delays", fill: "#c2b280"},
{source: "49: product development delays", target: "49: effectiveness", fill: "#c2b280"},
{source: "49: effectiveness", target: "49: technology", fill: "#c2b280"},
{source: "49: technology", target: "49: termination", fill: "#c2b280"},
{source: "49: termination", target: "49: trials altogether", fill: "#c2b280"},
{source: "49: delays could", target: "193: extremely volatile", fill: "#ff91a4"},
{source: "193: extremely volatile", target: "193: stock could", fill: "#ff91a4"},
{source: "193: extremely volatile", target: "204: listing on", fill: "#0072bb"},
{source: "204: listing on", target: "204: which could adversely affect", fill: "#0072bb"},
{source: "204: which could adversely affect", target: "204: common stock", fill: "#0072bb"},
{source: "204: common stock", target: "204: penny stock rules", fill: "#0072bb"},
{source: "204: listing on", target: "START_HERE", fill: "#0072bb"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_differentiation">Product differentiation</a></td>
      <td>In economics and marketing, product differentiation (or simply differentiation) is  \nthe process of distinguishing a product or service from others, to make it more attractive to a particular target market. This involves differentiating it from competitors' products as well as a firm's own products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_product_development">New product development</a></td>
      <td>In business and engineering, new product development (NPD) covers the complete process of bringing a new product to market, renewing an existing product or introducing a product in a new market. A central aspect of NPD is product design, along with various business considerations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Structured_product">Structured product</a></td>
      <td>A structured product, also known as a market-linked investment, is a pre-packaged structured finance investment strategy based on a single security, a basket of securities, options, indices, commodities, debt issuance or foreign currencies, and to a lesser extent, derivatives.\nStructured products are not homogeneous — there are numerous varieties of derivatives and underlying assets — but they can be classified under the aside categories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Carbon_Border_Adjustment_Mechanism">Carbon Border Adjustment Mechanism</a></td>
      <td>The Carbon Border Adjustment Mechanism (CBAM) is a proposed carbon tariff on carbon intensive products, such as cement and some electricity, imported by the European Union. Currently being legislated as part of the European Green Deal it is likely to take effect in 2026 with reporting starting in 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GENAERA CORP      ITEM 1A RISK FACTORS        Any <font color="blue">investment</font> in shares of our <font color="blue"><font color="blue">common stock</font> involves</font> a high degree of risk</td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider each of the <font color="blue">following risk factors together</font>     with the other information presented in this <font color="blue">Annual Report </font>on Form 10-K       Risks Related to Our Business        If we do not <font color="blue"><font color="blue">raise <font color="blue">additional</font></font> capital</font>, we may not be able to continue our     research and <font color="blue"><font color="blue">development</font> programs</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may never <font color="blue">commercialize</font></font> any products</td>
    </tr>
    <tr>
      <td>We maintained cash, cash equivalents and short-term <font color="blue">investment</font>s of dlra32dtta2     <font color="blue">million at</font> <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We believe these resources are sufficient to     <font color="blue">sustain <font color="blue">operations</font></font> and meet our research and <font color="blue"><font color="blue">development</font> goals at least</font>     through 2006</td>
    </tr>
    <tr>
      <td>However, we will need to raise substantial <font color="blue"><font color="blue">additional</font> funds</font> in     the  future  to  continue our research and <font color="blue"><font color="blue">development</font> programs</font> and to     <font color="blue">commercialize</font> our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">raise <font color="blue">additional</font></font>     funds, we may be unable to complete our <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font> for any of     our <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">regularly explore <font color="blue">alternative</font></font> means of financing our <font color="blue">operations</font> and seek     <font color="blue">funding through various sources</font>, including public and <font color="blue">private securities</font>     offerings, collaborative <font color="blue">arrangements</font> <font color="blue">with <font color="blue">third parties</font></font> and other strategic     alliances  and  business  <font color="blue"><font color="blue">transaction</font>s</font></td>
    </tr>
    <tr>
      <td>We  currently do not have any     <font color="blue">commitments from</font> other parties to provide us <font color="blue"><font color="blue">additional</font> funds</font> and may be     unable to obtain <font color="blue">sufficient funding</font> in the future on acceptable terms, if at     all</td>
    </tr>
    <tr>
      <td>If we cannot obtain funding, we will need to delay, scale back or     <font color="blue">eliminate research</font> and <font color="blue"><font color="blue">development</font> programs</font> or <font color="blue">enter into <font color="blue">collaborations</font></font>     <font color="blue">with <font color="blue">third parties</font></font> to <font color="blue">commercialize</font> <font color="blue">potential products</font> or <font color="blue">technologies</font> that     we <font color="blue">might otherwise seek</font> to develop or <font color="blue">commercialize</font> ourselves, or seek other     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">raise <font color="blue">additional</font></font> capital</font> by issuing equity securities or securities     <font color="blue">convertible into equity</font>, the <font color="blue">issuance may</font> result in <font color="blue">ownership dilution</font> to     our  <font color="blue">stockholders</font>  and our share <font color="blue">price may decline</font></td>
    </tr>
    <tr>
      <td>The extent of such     <font color="blue">dilution will vary based upon</font> the amount of <font color="blue">capital raised</font></td>
    </tr>
    <tr>
      <td>Capital raising efforts through <font color="blue">collaborations</font> may eventually negatively     impact our <font color="blue">financial interests</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">raise <font color="blue">additional</font></font> capital</font> through <font color="blue">collaborations</font> and licensing we may     give  up valuable rights in <font color="blue"><font color="blue">intellectual</font> property</font> and the value of our     interest in the <font color="blue">licensed products could</font> be <font color="blue">negatively impacted by competing</font>     strategic and <font color="blue">financial interests</font> of our <font color="blue">collaborators</font> or licensees</td>
    </tr>
    <tr>
      <td>If we     engage  in  <font color="blue">collaborations</font>,  we  may  receive <font color="blue">lower consideration upon</font>     <font color="blue">commercialization</font> of <font color="blue"><font color="blue">such products</font> than</font> if we had not <font color="blue">entered into such</font>     <font color="blue">arrangements</font>, or if we had <font color="blue">entered into such</font> <font color="blue">arrangements</font> at later stages in     the <font color="blue">product <font color="blue">development</font> process</font></td>
    </tr>
    <tr>
      <td>8     ______________________________________________________________________    [32]Table of <font color="blue">Contents       </font>We expect to continue to incur substantial losses in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We do not now have, nor have we ever had, <font color="blue">products available</font> for commercial     sale and we <font color="blue"><font color="blue">may never generate revenue</font>s</font> or <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>To date, we have engaged primarily in the research and <font color="blue">development</font> of drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have not generated any <font color="blue">revenues from product sales</font> and have     <font color="blue">incurred losses</font> in <font color="blue">each year since</font> our inception</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005,     we had an <font color="blue">accumulated deficit</font> of dlra239dtta5 million</td>
    </tr>
    <tr>
      <td>Our <font color="blue">proposed products</font> are in a <font color="blue">relatively</font> early <font color="blue">development</font>al stage and will     require  <font color="blue">significant</font> research, <font color="blue">development</font> and testing</td>
    </tr>
    <tr>
      <td>We must obtain     <font color="blue"><font color="blue">regulatory</font> approvals</font> for any <font color="blue">proposed product prior</font> to <font color="blue">commercialization</font> of     the product</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are also subject to <font color="blue">various <font color="blue">competitive</font></font> and     <font color="blue"><font color="blue">regulatory</font> risks</font></td>
    </tr>
    <tr>
      <td>We expect to experience     substantial losses in the <font color="blue">foreseeable future</font> as we continue our research,     <font color="blue">development</font> and <font color="blue">testing efforts</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry        Development and commercial <font color="blue">introduction</font> of our <font color="blue">products will</font> take several     more years and may not be successful</td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">dedicating <font color="blue">substantially</font></font> all of our resources to research and     <font color="blue">development</font>, do not have any <font color="blue">marketed products</font> and have not generated any     product  revenue</td>
    </tr>
    <tr>
      <td>Because <font color="blue">substantially</font> all of our <font color="blue">potential products</font>     currently are in research, preclinical <font color="blue">development</font> or the early and middle     stages of clinical testing, revenues from sales of any <font color="blue">products will</font> not     occur for at least the <font color="blue">next several years</font>, if at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">technologies</font> are     <font color="blue"><font color="blue">relatively</font> new fields</font> and may not lead to <font color="blue"><font color="blue">commercially</font> viable <font color="blue">pharmaceutical</font></font>     products</td>
    </tr>
    <tr>
      <td>Before we can <font color="blue"><font color="blue">commercially</font> introduce</font> any products, we <font color="blue">will likely</font>     incur substantial expense for, and devote a <font color="blue"><font color="blue">significant</font> amount</font> of time to,     <font color="blue">preclinical testing</font> and <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot apply</font> for <font color="blue">regulatory</font>     approval  of our <font color="blue">potential products</font> until we have performed <font color="blue">additional</font>     research and <font color="blue">development</font> testing and <font color="blue"><font color="blue">demonstrate</font>d</font> in <font color="blue">preclinical testing</font> and     <font color="blue">clinical trials</font> that our product <font color="blue">candidates</font> are safe and <font color="blue">effective</font> for use     in  humans</td>
    </tr>
    <tr>
      <td>Some of our product <font color="blue">candidates</font> are in the <font color="blue">early stages</font> of     research and <font color="blue">development</font> and we may abandon further <font color="blue">development</font> efforts on     these product <font color="blue">candidates</font> before they reach <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conducting     </font><font color="blue">clinical trials</font> is a lengthy, time-consuming and <font color="blue">expensive process</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">clinical trials</font> may not <font color="blue">demonstrate</font> the safety and efficacy of our potential     products and we <font color="blue">may encounter</font> unacceptable side effects or other problems in     the <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Should this occur, we may have to delay or <font color="blue">discontinue</font>     <font color="blue">development</font> of the <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Further, even if we believe that a     product is safe or <font color="blue">effective</font>, we may not obtain the required <font color="blue">regulatory</font>     approvals, be able to <font color="blue">manufacture</font> our products in <font color="blue">commercial quantities</font> or     be able to market any <font color="blue">product <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical  </font>testing  and clinical <font color="blue">development</font> are long, expensive and     <font color="blue">uncertain processes</font></td>
    </tr>
    <tr>
      <td>It may take <font color="blue">us several years</font> to complete our testing     and  failure can occur at any stage of testing</td>
    </tr>
    <tr>
      <td>We <font color="blue">may suffer <font color="blue">significant</font> setbacks</font> in <font color="blue">advanced clinical</font>     trials, even after promising results in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>We may not be able     to enroll a sufficient number of patients to complete our <font color="blue">clinical trials</font> in     a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Based on results at any stage of <font color="blue">clinical trials</font>, we may     decide to <font color="blue">discontinue</font> <font color="blue">development</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">recruit patients</font> could delay or prevent <font color="blue">clinical trials</font> of our     potential  products,  which  could delay or prevent the <font color="blue">development</font> of     <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Identifying </font>and qualifying patients to <font color="blue">participate</font> in <font color="blue">clinical trials</font> of our     <font color="blue">potential products</font> is <font color="blue">critically</font> important to our success</td>
    </tr>
    <tr>
      <td>The timing of our     <font color="blue">clinical trials</font> depends on the <font color="blue">speed at which</font> we can <font color="blue">recruit patients</font> to     <font color="blue">participate</font> in testing our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have experienced delays in     some of our <font color="blue">clinical trials</font> and we may experience similar delays in the     future</td>
    </tr>
    <tr>
      <td>If patients are unwilling to <font color="blue">participate</font> in our trials because of     <font color="blue">competitive</font> <font color="blue">clinical trials</font> for similar <font color="blue">patient populations</font>, the timeline     for recruiting patients, conducting trials and obtaining <font color="blue">regulatory</font> approval     of  potential  products  will be delayed</td>
    </tr>
    <tr>
      <td>These <font color="blue">delays could</font> result in     increased costs, delays in advancing our product <font color="blue">development</font>, delays in     testing the <font color="blue">effective</font>ness of our <font color="blue">technology</font> or <font color="blue">termination</font> of the clinical     <font color="blue">trials altogether</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with extensive <font color="blue"><font color="blue">government</font> <font color="blue">regulations</font></font> to which we are subject is     expensive and time consuming, and may result in the delay, cessation or     <font color="blue">cancellation</font> of product sales, <font color="blue">introduction</font>s or <font color="blue">modifications</font></td>
    </tr>
    <tr>
      <td><font color="blue">Extensive  </font>industry  regulation  has had, and <font color="blue">will continue</font> to have, a     <font color="blue"><font color="blue">significant</font> impact on</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Bio<font color="blue">pharmaceutical</font> </font>companies, like us,     are subject to extensive, complex, costly and <font color="blue">evolving regulation by</font> the     federal <font color="blue">government</font>, principally the FDA, and to a <font color="blue">lesser extent by</font> the US     Drug Enforcement Administration (“DEA”) and foreign and state <font color="blue">government</font>     agencies</td>
    </tr>
    <tr>
      <td>The Federal Food, Drug and Cosmetic Act, the Controlled Substances     Act  and other domestic and <font color="blue">foreign statutes</font> and <font color="blue"><font color="blue">regulations</font> govern</font> or     influence the testing, <font color="blue">manufacturing</font>, packing, labeling, storing, record     keeping, safety, approval, advertising, promotion, sale and <font color="blue">distribution</font> of     our  products</td>
    </tr>
    <tr>
      <td>Under certain of these <font color="blue">regulations</font>, we and our contract     suppliers and <font color="blue">manufacture</font>rs could be subject to <font color="blue">periodic inspection</font> of our     or their respective facilities, procedures and <font color="blue">operations</font> and/or the testing     of our <font color="blue">products by</font> the FDA, the DEA and other <font color="blue">authorities</font>, which conduct     <font color="blue">periodic inspection</font>s to confirm that we                                           9     ______________________________________________________________________    [33]Table of <font color="blue">Contents       </font>and our <font color="blue">contract suppliers</font> and <font color="blue">manufacture</font>rs are in <font color="blue">compliance with</font> all     applicable <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The FDA also conducts pre-approval and post-approval     reviews and <font color="blue">plant inspections</font> to determine whether our systems, or our     <font color="blue">contract suppliers</font>’ and <font color="blue">manufacture</font>rs’ processes, are in <font color="blue">compliance with</font>     current <font color="blue">Good Manufacturing Practices </font>(“cGMP”) and other FDA <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> receiving and maintaining FDA and other <font color="blue">government</font>al     approvals in order to produce and conduct <font color="blue">clinical trials</font> on our products</td>
    </tr>
    <tr>
      <td>There  is  always a risk that the FDA or other applicable <font color="blue">government</font>al     <font color="blue"><font color="blue">authorities</font> will</font> not approve our products, or will take post–approval action     limiting, modifying or revoking our ability to <font color="blue">manufacture</font> or sell our     products, or that the rate, timing and cost of <font color="blue">such approvals will <font color="blue">adversely</font></font>     affect our product <font color="blue">introduction</font> plans or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Governmental </font><font color="blue"><font color="blue">authorities</font> may delay</font> or deny the approval of any of our drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">government</font>al <font color="blue">authorities</font> may enact new legislation     or <font color="blue">regulations</font> that <font color="blue">could limit</font> or restrict our efforts</td>
    </tr>
    <tr>
      <td>A delay or denial     of <font color="blue">regulatory</font> approval for any of our drug <font color="blue">candidates</font> will have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td>Even if we receive approval of a product     candidate,  approval  may  be <font color="blue">conditioned upon certain limitations</font> and     <font color="blue">restrictions as</font> to the drugs used and may be subject to <font color="blue">continuous review</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> any applicable <font color="blue">regulatory</font> <font color="blue">requirements</font>, we could     be subject to penalties, including warning letters, fines, withdrawal of     <font color="blue">regulatory</font> approval, product recalls, operating restrictions, injunctions     and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">rely on <font color="blue">third parties</font></font> to market any products we develop and     expect to <font color="blue">rely on <font color="blue">third parties</font></font> in <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">development</font> of our     products;  if  these  parties do not perform as expected, we may never     <font color="blue">successfully</font> <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We do not have our own sales and <font color="blue">marketing staff</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">successfully</font>     develop and market our <font color="blue">future products</font>, we must develop this <font color="blue">infrastructure</font>     <font color="blue">with inherent risks</font> or <font color="blue">enter into marketing</font> and <font color="blue">distribution</font> <font color="blue">arrangements</font>     <font color="blue">with <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>We also expect to delegate the <font color="blue">responsibility</font> for all,     or a <font color="blue">significant</font> portion, of the <font color="blue">development</font> and <font color="blue">regulatory</font> approval for     certain  products to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If these parties do not develop an     approvable or marketable product or do not market a <font color="blue">product <font color="blue">successfully</font></font>, we     <font color="blue">may never generate revenue</font> or <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>Additionally, we may be     unable to enter into successful <font color="blue">arrangements</font> with other parties for such     products</td>
    </tr>
    <tr>
      <td>We currently have collaborative <font color="blue">agreements</font> with three primary <font color="blue">collaborators</font>:     MedImmune,  Inc,  Ludwig  Institute  of  Cancer Research (“LICR”) and     Laboratorios Bago SA We do not have <font color="blue">control over</font> the amount and timing of     resources to be devoted to our <font color="blue">products by</font> our <font color="blue">collaborative partners</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborators</font>  may  not  place  a  high  <font color="blue">priority on</font> their <font color="blue">contractual</font>     <font color="blue">arrangements</font> with us</td>
    </tr>
    <tr>
      <td><font color="blue">Collaborators </font>may develop <font color="blue">products <font color="blue">independently</font></font> or     through <font color="blue">third parties</font> that <font color="blue">could compete with</font> our <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>In     addition, a <font color="blue">collaborator may decide</font> to end a <font color="blue">relationship with us</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also may decide</font> to establish our own <font color="blue">sales force</font> to market and sell     <font color="blue">certain products</font></td>
    </tr>
    <tr>
      <td>Although some members of our <font color="blue">management</font> have limited     experience in marketing <font color="blue">pharmaceutical</font> products, we have no experience with     respect to marketing our products</td>
    </tr>
    <tr>
      <td>If we choose to pursue this <font color="blue">alternative</font>,     we will need to spend <font color="blue">significant</font> <font color="blue"><font color="blue">additional</font> funds</font> and devote <font color="blue">significant</font>     <font color="blue">management</font> resources and time to establish a successful <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">effort may</font> not be successful</td>
    </tr>
    <tr>
      <td>Moreover, because our <font color="blue">financial resources</font> are     limited, our sales and <font color="blue">marketing <font color="blue">expenditures</font></font> in this <font color="blue">area would likely</font> be     modest compared to that of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face formidable <font color="blue">competition</font> with respect</font> to the products we are seeking     to develop</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is <font color="blue">characterized by intense <font color="blue">competition</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>companies, research <font color="blue">institutions</font> and <font color="blue">universities</font> are <font color="blue">conducting research</font>     and  <font color="blue">development</font>  <font color="blue">activities</font>  in our fields of interest</td>
    </tr>
    <tr>
      <td>Most of these     <font color="blue">competitors</font> have <font color="blue">substantially</font> greater financial, technical, <font color="blue">manufacturing</font>,     marketing, <font color="blue">distribution</font> and other <font color="blue">resources than</font> we have</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also face</font>     <font color="blue"><font color="blue">competition</font> from companies using different</font> or <font color="blue">advanced techniques</font> that could     render our <font color="blue">future products</font> obsolete</td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">must continue</font> to devote     substantial resources and efforts to research and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font> in     order to maintain a <font color="blue"><font color="blue">competitive</font> position</font> in our fields</td>
    </tr>
    <tr>
      <td>Our <font color="blue">efforts may</font> not     be successful</td>
    </tr>
    <tr>
      <td>Many companies are working to develop and <font color="blue">market products intended</font> for     <font color="blue">additional</font> <font color="blue">disease areas</font> being <font color="blue">targeted by us</font>, including age-related macular     <font color="blue">degeneration</font> (“AMD”), cancer and <font color="blue"><font color="blue">respiratory</font> diseases</font></td>
    </tr>
    <tr>
      <td>A number of major     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> have <font color="blue">significant</font> franchises in these <font color="blue">disease areas</font>     and can be expected to <font color="blue">invest heavily</font> to protect their interests</td>
    </tr>
    <tr>
      <td><font color="blue">With     </font>respect to AMD, anti-angiogenic agents are under <font color="blue">development</font> at a number of     bio<font color="blue"><font color="blue">pharmaceutical</font> companies</font>, including Alcon, Inc, Bausch &amp; Lomb, Inc,     Genentech, Inc, Miravant Medical Technologies, OSI Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>and QLT, Inc, as well as other large <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>For cancer,     anti-angiogenic   agents   are   under  <font color="blue">development</font>  at  a  number  of     bio<font color="blue"><font color="blue">pharmaceutical</font> companies</font>, including EntreMed, Inc, Genentech, Inc</td>
    </tr>
    <tr>
      <td>and     Imclone Systems, Inc, as well as other large <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>In     the <font color="blue">respiratory</font> field, other bio<font color="blue"><font color="blue">pharmaceutical</font> companies</font> also have reported     the <font color="blue">discovery</font> of genes relating to asthma and other <font color="blue"><font color="blue">respiratory</font> diseases</font>,     including Genentech, Inc, Amgen, Inc</td>
    </tr>
    <tr>
      <td>and Vertex Pharmaceuticals, Inc, as     well  as  other  large <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>Many of the companies     developing or <font color="blue">marketing competing products</font>                                           10     ______________________________________________________________________    [34]Table of <font color="blue">Contents       </font>have <font color="blue">significant</font>ly more experience than we do in undertaking preclinical     testing and human <font color="blue">clinical trials</font> of new or <font color="blue">improved therapeutic products</font>     and obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font> of <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Some of these companies     may be in advanced phases of clinical testing of various drugs that may be     <font color="blue">competitive</font> with our <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>We expect technological <font color="blue">development</font>s in the <font color="blue">bio<font color="blue">pharmaceutical</font></font> field to occur     at a rapid rate and expect <font color="blue">competition</font> to <font color="blue">intensify as advances</font> in this     field are made</td>
    </tr>
    <tr>
      <td>Some of these companies are currently involved in research     and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font> focused on the <font color="blue">pathogenesis</font> of disease and the     <font color="blue">competition</font> among companies attempting to <font color="blue">find genes responsible</font> for disease     is intense</td>
    </tr>
    <tr>
      <td>In addition, we are aware that others are <font color="blue">conducting research</font> on     compounds derived from animal host-defense systems</td>
    </tr>
    <tr>
      <td>Colleges, <font color="blue">universities</font>, <font color="blue">government</font>al agencies and other public and private     <font color="blue">research <font color="blue">organizations</font></font> are becoming more active in <font color="blue">seeking patent protection</font>     and licensing <font color="blue">arrangements</font> to <font color="blue">collect royalties</font> for use of <font color="blue">technology</font> that     they have developed, some of which may be directly <font color="blue">competitive</font> with our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we are unable to recruit and retain <font color="blue">skilled employees</font>, we may not be able     to achieve our <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td><font color="blue">Retaining  </font>our  current  employees and <font color="blue">recruiting qualified scientific</font>     personnel to perform <font color="blue">future research</font> and <font color="blue">development</font> work will be critical     to our success</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">pharmaceutical</font> and specialized bio<font color="blue">technology</font>     companies, colleges, <font color="blue">universities</font>, <font color="blue">government</font>al agencies and other public     and private <font color="blue">research <font color="blue">organizations</font></font> can be expected to <font color="blue">compete with us</font> in     <font color="blue">recruiting highly qualified scientific personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>is intense for     experienced  <font color="blue">scientists</font>,  and  we may not be able to retain or recruit     sufficient  <font color="blue">skilled personnel</font> to allow us to pursue <font color="blue">collaborations</font> and     develop our products and core <font color="blue">technologies</font> to the <font color="blue">extent otherwise possible</font></td>
    </tr>
    <tr>
      <td>If we do not develop and maintain relationships with contract <font color="blue">manufacture</font>rs,     we may not <font color="blue">successfully</font> <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We currently do not have the resources, facilities or <font color="blue">technical capabilities</font>     to <font color="blue">manufacture</font> any of our <font color="blue">proposed products</font> in the quantities and quality     required for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>We have no plans to establish a <font color="blue">manufacturing</font>     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We expect to depend upon contract <font color="blue">manufacture</font>rs for commercial     scale <font color="blue">manufacturing</font> of our <font color="blue">proposed products</font> in <font color="blue">accordance</font> with <font color="blue">regulatory</font>     standards</td>
    </tr>
    <tr>
      <td>For example, we are currently working <font color="blue">with outside <font color="blue">contractors</font></font>     for the <font color="blue">chemical production</font> of squalamine</td>
    </tr>
    <tr>
      <td>This <font color="blue">dependence on contract</font>     <font color="blue">manufacture</font>rs may restrict our ability to develop and deliver <font color="blue">products on</font> a     timely, profitable and <font color="blue">competitive</font> basis especially because the number of     <font color="blue">companies capable</font> of producing our <font color="blue">proposed products</font> is limited</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>contract <font color="blue">manufacture</font>rs generally have multiple projects and they may give     ours a <font color="blue">lower priority</font></td>
    </tr>
    <tr>
      <td>As a result of contract <font color="blue">manufacturing</font> mishaps, our     product  could  be  lost  or delivered late, delaying our clinical and     preclinical programs, or may not be produced in <font color="blue">accordance</font> with all current     applicable <font color="blue">regulatory</font> standards</td>
    </tr>
    <tr>
      <td>Product not produced in <font color="blue">accordance</font> with all     current applicable <font color="blue">regulatory</font> standards may lead to <font color="blue">adverse outcomes</font> for     patients and/or product recalls</td>
    </tr>
    <tr>
      <td>Furthermore, the <font color="blue">development</font> of a robust,     low-cost <font color="blue">manufacturing</font> process for the <font color="blue">commercial production</font> of squalamine     and other <font color="blue">proposed products</font> will require <font color="blue">significant</font> time and <font color="blue">expenditure by</font>     us</td>
    </tr>
    <tr>
      <td>We  may be unable to maintain <font color="blue">arrangements</font> with qualified outside     <font color="blue">contractors</font> to <font color="blue">manufacture</font> materials at costs that are affordable to us, if     at all</td>
    </tr>
    <tr>
      <td>Contract <font color="blue">manufacture</font>rs may utilize their own <font color="blue">technology</font>, our <font color="blue">technology</font> or     <font color="blue">technology</font>  acquired  or  licensed  from <font color="blue">third parties</font> in developing a     <font color="blue">manufacturing</font> process</td>
    </tr>
    <tr>
      <td>In order to engage another <font color="blue">manufacture</font>r, we may need     to obtain a license or other <font color="blue">technology</font> transfer from the <font color="blue">original contract</font>     <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>Even if a license is <font color="blue">available from</font> the <font color="blue">original contract</font>     <font color="blue">manufacture</font>r on acceptable terms, we may be unable to <font color="blue">successfully</font> effect     the transfer of the <font color="blue">technology</font> to the new contract <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">technology</font> transfer may also require the transfer of <font color="blue">requisite data</font> for     <font color="blue">regulatory</font> purposes, including information contained in a <font color="blue"><font color="blue">proprietary</font> drug</font>     master  file held by a contract <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>If we rely on a contract     <font color="blue">manufacture</font>r that owns the <font color="blue">drug master file</font>, our ability to change contract     <font color="blue">manufacture</font>rs may be more limited</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our <font color="blue"><font color="blue">intellectual</font> property</font> and, if we are unable to protect our     <font color="blue"><font color="blue">intellectual</font> property</font>, our business may be harmed</td>
    </tr>
    <tr>
      <td>Patents        Our <font color="blue">success depends</font>, in part, on our ability to develop and maintain a     <font color="blue">strong <font color="blue">patent position</font></font> for our products and <font color="blue">technologies</font>, both in the United     States and other countries</td>
    </tr>
    <tr>
      <td>As with most bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font>     companies, our <font color="blue">patent position</font> is <font color="blue">highly uncertain</font> and <font color="blue">involves complex</font>     legal and factual questions</td>
    </tr>
    <tr>
      <td>Without patent and other <font color="blue">protections</font>, other     companies could offer <font color="blue">substantially</font> identical products for <font color="blue">sale without</font>     incurring the sizeable <font color="blue">development</font> and <font color="blue">testing costs</font> that we have incurred</td>
    </tr>
    <tr>
      <td>As a result, our ability to recover these <font color="blue">expenditures</font> and realize profits     upon <font color="blue">commercialization</font> would likely be diminished</td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font>after <font color="blue">significant</font> expenditure, a <font color="blue">patent may</font> not issue</td>
    </tr>
    <tr>
      <td>We can never be     certain that we were the first to develop the <font color="blue">technology</font> or that we were the     first to file a <font color="blue">patent <font color="blue">application</font></font> for the particular <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>US     patent  <font color="blue"><font color="blue">application</font>s</font>  are maintained in <font color="blue">secrecy by</font> the US Patent and     <font color="blue">Trademark Office </font>until a <font color="blue">patent issues</font> and <font color="blue">publications</font> in the scientific or     patent literature <font color="blue">concerning</font> new <font color="blue">technologies</font> occur some time after actual     <font color="blue">discoveries</font> of the <font color="blue">technologies</font> are made</td>
    </tr>
    <tr>
      <td>We cannot be certain that:           •   <font color="blue">patents will</font> issue from any of our <font color="blue">patent <font color="blue">application</font></font>s;           •   our <font color="blue">patent rights will</font> be sufficient to protect our <font color="blue">technology</font>;           •   <font color="blue">others may</font> not <font color="blue">file patents ahead</font> of us in time and prevent the     issuing of our patent claims;           •   <font color="blue">others will</font> not <font color="blue">design around</font> the <font color="blue">patented aspects</font> of our <font color="blue">technology</font>;     or           •   our <font color="blue">patents will</font> not be <font color="blue">successfully</font> challenged or <font color="blue">circumvented by</font> our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>The cost of <font color="blue">litigation</font> related to patents can be substantial, <font color="blue">regardless</font> of     the outcome</td>
    </tr>
    <tr>
      <td>We own <font color="blue">several patents</font> and <font color="blue">patent <font color="blue">application</font></font>s for the use of <font color="blue">squalamine as</font>     an  anti-angiogenic, including methods for the treatment of cancer and     <font color="blue">neovascularization</font> in the eye</td>
    </tr>
    <tr>
      <td>One of these patents is to the compound’s     <font color="blue">combination therapy with</font> other anti-cancer agents and will expire in 2017,     while  another  patent  covers  the  treatment  of age-related macular     <font color="blue">degeneration</font>, retinopathy of <font color="blue">prematurity</font> and <font color="blue">diabetic retinopathy</font> and will     expire in 2015</td>
    </tr>
    <tr>
      <td>We also own <font color="blue"><font color="blue">patents covering</font> methods</font> and <font color="blue">intermediates</font> in     the <font color="blue">manufacturing</font> process of squalamine and <font color="blue">trodusquemine</font> that expire in     2017,  2018  and  2021</td>
    </tr>
    <tr>
      <td>We own a <font color="blue">composition</font> of matter patent for the     <font color="blue">trodusquemine</font> compound, <font color="blue">which expires</font> in 2014</td>
    </tr>
    <tr>
      <td>We also own a patent for the     use of <font color="blue">trodusquemine</font> as an anti-obesity agent and other <font color="blue">indications</font> that     expires in 2015</td>
    </tr>
    <tr>
      <td>We own two patents for the use of anti-IL9 or anti-IL9     <font color="blue">receptor antibodies</font> for the treatment of asthma and related disorders that     expire in 2016</td>
    </tr>
    <tr>
      <td>We also have US <font color="blue">patents covering</font> the <font color="blue">composition</font> of a     matter for a mucoregulator target and another <font color="blue">patent covering methods</font> for     screening for <font color="blue">mucoregulator compounds</font> that both expire in 2019</td>
    </tr>
    <tr>
      <td>We own a     <font color="blue">patent on</font> the use of <font color="blue">talniflumate</font> and related <font color="blue">mucoregulator compounds</font> for     <font color="blue">treating various conditions</font> where mucous is overproduced, <font color="blue">which expires</font> in     2021</td>
    </tr>
    <tr>
      <td>The  expiration  date of each of these patents is subject to extension     <font color="blue">depending upon</font> the <font color="blue">future research</font> and <font color="blue">development</font> program timelines</td>
    </tr>
    <tr>
      <td>We     have <font color="blue">filed several</font> other <font color="blue"><font color="blue">application</font>s</font> across our research and <font color="blue">development</font>     programs and intend to file <font color="blue">additional</font> <font color="blue"><font color="blue">application</font>s</font>, as appropriate, for     patents on new compounds, products or <font color="blue">processes discovered</font> or developed     through the <font color="blue">application</font> of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We have rights to <font color="blue">several patents</font> and <font color="blue">patent <font color="blue">application</font></font>s under certain     <font color="blue">license <font color="blue">agreements</font> pursuant</font> to which we expect to <font color="blue">owe <font color="blue">royalties on sales</font></font> of     products that <font color="blue">incorporate issued valid patent</font> claims</td>
    </tr>
    <tr>
      <td>In particular, we have     <font color="blue">licensed from</font> the <font color="blue">Ludwig Institute of Cancer Research </font>specific <font color="blue">technologies</font>     related to our IL9 program, the earliest of <font color="blue">which expires</font> in 2009</td>
    </tr>
    <tr>
      <td>We have     <font color="blue">licensed from</font> the Children’s Hospital of Philadelphia the <font color="blue">composition</font> of     matter patent for the squalamine compound, <font color="blue">which expires</font> in 2012</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>patents are subject to <font color="blue">extensions by</font> their owners <font color="blue">depending upon</font> the future     research and <font color="blue">development</font> program timelines</td>
    </tr>
    <tr>
      <td>Additionally, certain of these     <font color="blue">agreements</font>  <font color="blue">also provide</font> that if we elect not to pursue the commercial     <font color="blue">development</font> of any licensed <font color="blue">technology</font>, or do not adhere to an acceptable     schedule of <font color="blue">commercialization</font>, then our <font color="blue">exclusive rights</font> to such <font color="blue">technology</font>     <font color="blue">may terminate</font></td>
    </tr>
    <tr>
      <td>Third Party Intellectual Property Rights        We cannot be sure that our products do not <font color="blue">infringe on</font> the <font color="blue">intellectual</font>     <font color="blue">property rights</font> of others and we may have <font color="blue">infringement</font> claims asserted     <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>These claims may harm our reputation, cost us money and prevent     <font color="blue">us from offering</font> some products</td>
    </tr>
    <tr>
      <td>Any claims or <font color="blue">litigation</font> in this area may be     costly  and  could  result  in large awards <font color="blue">against us</font> and, whether we     <font color="blue">ultimately win</font> or lose, could be time-consuming, may injure our reputation,     may result in <font color="blue">costly delays</font> or may require us to <font color="blue">enter into royalty</font> or     licensing <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>If there is a successful claim of <font color="blue">infringement</font>     <font color="blue">against us</font> or if we fail to develop non-infringing <font color="blue">technology</font> or license the     <font color="blue">proprietary</font>  rights  on  a  timely  basis,  our ability to use certain     <font color="blue">technologies</font>, products, services and brand <font color="blue">names may</font> be limited and our     business may be harmed</td>
    </tr>
    <tr>
      <td>Other Intellectual Property        We have <font color="blue">trademark protection</font> for the <font color="blue">product candidate names</font> EVIZON™ and     LOMUCIN™ and are currently seeking US <font color="blue">registration</font> of these <font color="blue">trademarks</font></td>
    </tr>
    <tr>
      <td>In     order to protect our <font color="blue">proprietary</font> <font color="blue">technology</font> and processes, we <font color="blue">also rely on</font>     trade  secrets  and  <font color="blue">confidentiality</font>  <font color="blue">agreements</font>  with  our employees,     <font color="blue">consultants</font>, outside scientific <font color="blue">collaborators</font> and other advisors</td>
    </tr>
    <tr>
      <td>We may     find that these <font color="blue">agreements</font> have <font color="blue">been breached</font> or that our <font color="blue">trade secrets</font> have     <font color="blue">otherwise become known</font> or <font color="blue">independently</font> developed or <font color="blue">discovered by</font> our     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________    [36]Table of <font color="blue">Contents       </font>Certain of our <font color="blue">exclusive rights</font> to patents and <font color="blue">patent <font color="blue">application</font></font>s are     governed by contract</td>
    </tr>
    <tr>
      <td>Generally, these contracts require that we undertake     <font color="blue">certain <font color="blue">obligations</font></font> including the payment of <font color="blue">royalties on sales</font> of any     products  that  are  <font color="blue">covered by patent</font> claims</td>
    </tr>
    <tr>
      <td>If we do not meet those     <font color="blue">obligations</font>, we may lose our rights</td>
    </tr>
    <tr>
      <td>Additionally, some of these <font color="blue">agreements</font>     also  require  that we develop the licensed <font color="blue">technology</font> or <font color="blue">meet certain</font>     <font color="blue"><font color="blue">milestones</font> within</font> a <font color="blue">given timeframe</font></td>
    </tr>
    <tr>
      <td>If we do not adhere to an acceptable     schedule of <font color="blue">commercialization</font>, we may lose our rights</td>
    </tr>
    <tr>
      <td>Potential Ownership Disputes        Disputes  may arise as to the ownership of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Most of our     research  and  <font color="blue">development</font>  personnel  have <font color="blue">previously</font> worked at other     bio<font color="blue">technology</font> companies, <font color="blue"><font color="blue">pharmaceutical</font> companies</font>, <font color="blue">universities</font> or research     <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">entities may raise questions as</font> to when <font color="blue">technology</font> was     developed and assert rights to the <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However, we may not     prevail in any <font color="blue">such disputes</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Similar  </font><font color="blue">technology</font>  ownership  disputes  may  arise in the context of     <font color="blue">consultants</font>, vendors or <font color="blue">third parties</font>, such as contract <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>For     example, our <font color="blue">consultants</font> are <font color="blue">employed by</font> or have consulting <font color="blue">agreements</font> with     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>There may be <font color="blue">disputes as</font> to the <font color="blue">capacity</font> in which <font color="blue">consultants</font>     are operating when they make certain <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>We may not prevail in any     <font color="blue">such disputes</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot recruit</font> and retain qualified <font color="blue">management</font>, we may not be able to     <font color="blue">successfully</font> develop and <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We depend to a considerable <font color="blue">degree on</font> a limited number of <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Most <font color="blue">significant</font> responsibilities have <font color="blue">been assigned</font> to a <font color="blue">relatively</font> small     number of <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td>In particular, it would be <font color="blue">difficult</font> to replace our     President and Chief Executive Officer, John L Armstrong, Jr</td>
    </tr>
    <tr>
      <td>We entered     into an <font color="blue">evergreen <font color="blue">employment</font> agreement with</font> Mr</td>
    </tr>
    <tr>
      <td>Armstrong, dated October 21,     2003, that is <font color="blue">terminable by either party</font></td>
    </tr>
    <tr>
      <td>This <font color="blue"><font color="blue">employment</font> agreement contains</font>     non-<font color="blue">competition</font> and non-solicitation clauses</td>
    </tr>
    <tr>
      <td>All of our executive officers     have executed individual <font color="blue">employment</font> <font color="blue">agreements</font> with us</td>
    </tr>
    <tr>
      <td>We do not maintain     “key man” insurance on any of our employees</td>
    </tr>
    <tr>
      <td>The loss of certain <font color="blue">management</font>     and <font color="blue">technical personnel could <font color="blue">adversely</font> affect</font> our ability to develop and     <font color="blue">commercialize</font> products</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">potential product <font color="blue">liability</font></font> claims that could result in     <font color="blue">significant</font> costs</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">significant</font> <font color="blue">potential product <font color="blue">liability</font></font> risks inherent in     the testing, <font color="blue">manufacturing</font> and marketing of <font color="blue">human therapeutic products</font>,     including the risk that:           •   our <font color="blue">proposed products</font> cause some undesirable side effects or injury     during <font color="blue">clinical trials</font>;           •   our products cause undesirable side effects or injury in the market;     or           •   <font color="blue">third parties</font> that we have agreed to <font color="blue">indemnify incur</font> a related     <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We currently maintain <font color="blue">primary products</font> and completed <font color="blue">operations</font> <font color="blue">liability</font>     <font color="blue">insurance with per occurrence</font> and <font color="blue">aggregate <font color="blue">coverage limits</font></font> of dlra8dtta0 million</td>
    </tr>
    <tr>
      <td>The <font color="blue">coverage limits</font> of our insurance policies may be inadequate to fully     <font color="blue">protect us from liabilities</font> we <font color="blue">might incur</font> in <font color="blue"><font color="blue">connection</font> with</font> clinical     trials, <font color="blue">manufacturing</font> and marketing of our products</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font>     insurance  is  expensive  and  in  the  <font color="blue">future may</font> not be <font color="blue">available on</font>     <font color="blue">commercially</font> acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>A successful claim or claims     brought <font color="blue">against us</font> in excess of our <font color="blue">insurance coverage could materially harm</font>     our business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If we do not receive adequate third-party <font color="blue">reimbursement</font> for any of our drug     <font color="blue">candidates</font>, some <font color="blue">patients may</font> be unable to afford our products and sales     <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>In both the <font color="blue">United States </font>and elsewhere, the <font color="blue">availability</font> of <font color="blue">reimbursement</font>     from  third-party  payers,  such  as  <font color="blue">government</font> health <font color="blue">administration</font>     <font color="blue">authorities</font>, private health insurers and other <font color="blue">organizations</font>, can impact     prescription <font color="blue">pharmaceutical</font> sales</td>
    </tr>
    <tr>
      <td>These <font color="blue">organizations</font> are <font color="blue">increasingly</font>     <font color="blue">challenging</font>  the  prices  charged  for  <font color="blue">medical products</font> and services,     <font color="blue">particularly</font>  where  they  believe  that  there is only an <font color="blue">incremental</font>     <font color="blue">therapeutic benefit</font> that does not justify the <font color="blue">additional</font> cost</td>
    </tr>
    <tr>
      <td>If any of our     products ever obtain marketing approval, coverage and <font color="blue">reimbursement</font> may not     be available for these products, or, if available, may not be adequate</td>
    </tr>
    <tr>
      <td><font color="blue">Without  </font>insurance coverage, many <font color="blue">patients may</font> be unable to afford our     products, in <font color="blue">which case sales</font> of the <font color="blue">products would</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>There also has been a trend toward <font color="blue">government</font> reforms intended to contain or     reduce the cost of <font color="blue">health care</font></td>
    </tr>
    <tr>
      <td>In certain foreign markets, pricing or     <font color="blue">profitability</font> of prescription <font color="blue">pharmaceutical</font>s is subject to <font color="blue">government</font>     control</td>
    </tr>
    <tr>
      <td>In the United States,                                           13     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font>there have been a number of federal and state proposals to implement similar     <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>We expect this trend to continue, but we <font color="blue">cannot predict</font>     the  nature  or extent of any reform that results</td>
    </tr>
    <tr>
      <td>These <font color="blue">reforms could</font>     <font color="blue">adversely</font>  affect  our  ability  to obtain financing for the continued     <font color="blue">development</font> of our <font color="blue">proposed products</font> or market any of our products that are     <font color="blue">successfully</font> developed</td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">reforms could</font> have a <font color="blue">broader impact by</font>     limiting  <font color="blue">overall growth</font> of <font color="blue">health care</font> spending, such as Medicare and     Medicaid spending, which could also <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>Risks Related to Our Stock        Our stock price is <font color="blue">extremely volatile</font> and your <font color="blue">investment</font> in our <font color="blue">stock could</font>     decline  in  value</td>
    </tr>
    <tr>
      <td>We <font color="blue">may become involved</font> in securities class action     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> and <font color="blue">trading volumes</font> for securities of <font color="blue">bio<font color="blue">pharmaceutical</font></font>     and bio<font color="blue">technology</font> companies, including ours, have <font color="blue">historically been</font>, and     <font color="blue">will likely</font> continue to be, <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">events affecting</font> our     business, or that of our <font color="blue">competitors</font>, may have a <font color="blue"><font color="blue">significant</font> impact on</font> our     stock price</td>
    </tr>
    <tr>
      <td>Among these events are the following:           •   <font color="blue">product testing</font> results from us or our <font color="blue">competitors</font>;           •   <font color="blue">technological innovations by us</font> or our <font color="blue">competitors</font>;           •   <font color="blue">new commercial products from us</font> or our <font color="blue">competitors</font>;           •   whether and when we achieve specified <font color="blue">development</font> or <font color="blue">commercialization</font>     <font color="blue">milestones</font>;           •   <font color="blue">regulatory</font> <font color="blue">development</font>s in the <font color="blue">United States </font>and foreign countries;           •   <font color="blue">development</font>s <font color="blue">concerning</font> <font color="blue">proprietary</font> rights, including patents;           •   <font color="blue">regulatory</font> actions;           •   <font color="blue">litigation</font>;           •   economic and other <font color="blue">external factors</font> or other <font color="blue">disasters</font> or crises;           •   period-to-period fluctuations in our financial results; and           •   the <font color="blue">general performance</font> of the <font color="blue">equity markets</font> and, in particular, the     bio<font color="blue">technology</font> sector of the <font color="blue">equity markets</font></td>
    </tr>
    <tr>
      <td>In the past two years our stock price on <font color="blue">the <font color="blue">Nasdaq SmallCap Market</font> </font>has     <font color="blue">fluctuated from</font> a low of dlra1dtta28 per share on <font color="blue">December </font>20, 2005 to a high of     dlra5dtta00 per share on January 27, 2004</td>
    </tr>
    <tr>
      <td>In 2005, our <font color="blue">stock price fluctuated</font>     from dlra1dtta28 to dlra3dtta50 per share, with an <font color="blue">average price</font> of approximately dlra2dtta09</td>
    </tr>
    <tr>
      <td>The <font color="blue">volatility</font> in our stock price is due to the <font color="blue">volatility</font> of our industry     in general and does not appear to be connected to any <font color="blue">event specific</font> to us</td>
    </tr>
    <tr>
      <td>In  the past, following periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a     particular company’s securities, securities class action <font color="blue">litigation</font> has     <font color="blue">often been brought against</font> that company</td>
    </tr>
    <tr>
      <td>We <font color="blue">may become involved</font> in this type     of <font color="blue">litigation</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>of this type is often extremely     expensive and diverts <font color="blue">management</font>’s attention and resources</td>
    </tr>
    <tr>
      <td>We  may  be unable to maintain the standards for <font color="blue">listing on</font> the Nasdaq     SmallCap Market, which could <font color="blue">adversely</font> affect the liquidity of our common     stock and could subject our <font color="blue">common stock</font> to the “<font color="blue">penny stock</font>” rules</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is <font color="blue">currently listed on</font> the <font color="blue">Nasdaq SmallCap Market</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>are <font color="blue">several <font color="blue">requirements</font></font> that we <font color="blue">must satisfy</font> in order for our <font color="blue">common stock</font>     to continue to be listed on the <font color="blue">Nasdaq SmallCap Market</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">requirements</font>     include, but are not limited to, maintaining a <font color="blue">minimum per</font> share price of     our <font color="blue">common stock</font> of dlra1dtta00 and a <font color="blue">minimum level</font> of <font color="blue">stockholders</font>’ equity of     dlra2dtta5 million</td>
    </tr>
    <tr>
      <td>In the future, we may not <font color="blue">comply with</font> all of these listing     <font color="blue">requirements</font>, which might result in the delisting of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delisting  </font>from  <font color="blue">the <font color="blue">Nasdaq SmallCap Market</font> </font>could <font color="blue">adversely</font> affect the     liquidity and the price of our <font color="blue">common stock</font> and could have a long-term     <font color="blue">adverse impact on</font> our ability to <font color="blue">raise future capital through</font> a sale of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> were delisted, our <font color="blue">common stock</font> would be traded on an     <font color="blue">electronic bulletin board established</font> for securities that are not included     on Nasdaq, traded on a <font color="blue">national securities exchange</font> or traded in quotations     <font color="blue">published by</font> the National Quotation Bureau, Inc, <font color="blue">commonly referred</font> to as     the  “pink  sheets</td>
    </tr>
    <tr>
      <td>” If this occurs, it could be <font color="blue">difficult</font> to sell our     securities or obtain the same level of market information as to the price of     our <font color="blue">common stock</font> as is <font color="blue">currently available</font></td>
    </tr>
    <tr>
      <td>In addition, if our <font color="blue">common stock</font> were delisted, it would be subject to the     so-called “<font color="blue">penny stock</font>” rules</td>
    </tr>
    <tr>
      <td>The SEC has adopted <font color="blue">regulations</font> that define a     “<font color="blue">penny stock</font>” to be any <font color="blue">equity security</font> that has a <font color="blue">market price</font> per share of     less than dlra5dtta00, subject to certain <font color="blue">exceptions</font>, such as any securities     listed  on a <font color="blue">national securities exchange</font> or quoted on Nasdaq</td>
    </tr>
    <tr>
      <td>For any     <font color="blue">transaction</font> involving a “<font color="blue">penny stock</font>,” unless exempt, the rules impose     <font color="blue">additional</font> sales practice <font color="blue">requirements</font> on broker-dealers, subject to certain     <font color="blue">exceptions</font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________    [38]Table of <font color="blue">Contents       </font>For <font color="blue"><font color="blue">transaction</font>s</font> covered by the “<font color="blue">penny stock</font>” rules, a broker-dealer must     make a special suitability de<font color="blue">termination</font> for the purchaser and must have     received the purchaser’s written consent to the <font color="blue">transaction</font> prior to the     <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>The “<font color="blue">penny stock</font>” rules also require broker-dealers to deliver     monthly  statements to “<font color="blue">penny stock</font>” investors disclosing <font color="blue">recent price</font>     information for the “<font color="blue">penny stock</font>” held in the account and information on the     limited market in “<font color="blue">penny stock</font>s</td>
    </tr>
    <tr>
      <td>” Prior to the <font color="blue">transaction</font>, a broker-dealer     must provide a <font color="blue">disclosure schedule</font> relating to the “<font color="blue">penny stock</font>” market</td>
    </tr>
    <tr>
      <td>In     addition, the broker-dealer must disclose the following:           •   <font color="blue">commissions payable</font> to the broker-dealer and the registered     <font color="blue">representative</font>; and           •   <font color="blue">current quotations</font> for the <font color="blue">security as mandated by</font> the applicable     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> were delisted and determined to be a “<font color="blue">penny stock</font>,” a     broker-dealer may find it more <font color="blue">difficult</font> to trade our <font color="blue">common stock</font> and an     <font color="blue">investor may find</font> it more <font color="blue">difficult</font> to acquire or dispose of our common     stock in the <font color="blue">secondary market</font></td>
    </tr>
    <tr>
      <td>The exercise of options and warrants and other issuances of <font color="blue">shares will</font>     likely have a dilutive effect on our stock price</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, there were <font color="blue">outstanding options</font> to purchase an     aggregate of 5cmam577cmam250 shares of our <font color="blue">common stock</font> at prices ranging from     dlra0dtta40 per share to dlra11dtta63 per share, of <font color="blue">which options</font> to purchase 2cmam275cmam187     shares were <font color="blue">exercisable as</font> of such date</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, there were     <font color="blue">outstanding warrants</font> to purchase 4cmam627cmam266 shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Of     this total, warrants to purchase 167cmam166 shares of our <font color="blue">common stock</font> are     currently exercisable at dlra3dtta33 per share, subject to <font color="blue">adjustment under</font> the     anti-dilution provisions of the warrants</td>
    </tr>
    <tr>
      <td>Warrants to purchase 50cmam000 and     990cmam100 shares are currently exercisable at dlra3dtta79 and dlra5dtta38 per share,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>2005, in <font color="blue"><font color="blue">connection</font> with</font> a <font color="blue">registered direct</font>     offering of our <font color="blue">common stock</font>, we issued to <font color="blue">institutional investors warrants</font>     to purchase 3cmam420cmam000 shares of our <font color="blue">common stock</font> at an <font color="blue">exercise price</font> of     dlra3dtta15 per share, which are <font color="blue">exercisable as</font> of March 13, 2006</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection</font>     with an April 2002 private placement of our <font color="blue">common stock</font>, we granted to the     <font color="blue">placement agent warrants</font> to purchase 100cmam000 shares of our <font color="blue">common stock</font> at     an  exercise  price of dlra2dtta75 per share</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, these     warrants have not <font color="blue">yet been issued</font></td>
    </tr>
    <tr>
      <td>The exercise of options and <font color="blue">warrants at prices</font> below the <font color="blue">market price</font> of our     common  stock  could  <font color="blue">adversely</font>  affect the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">dilution may</font> result from the issuance of shares of our capital     stock in <font color="blue"><font color="blue">connection</font> with</font> <font color="blue">collaborations</font> or <font color="blue">manufacturing</font> <font color="blue">arrangements</font> or in     <font color="blue"><font color="blue">connection</font> with</font> other <font color="blue">financing efforts</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue">Delaware </font><font color="blue">law contain provisions</font> that     <font color="blue">could discourage</font> a takeover and entrench <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> provides our board of <font color="blue">directors</font> the power     to  <font color="blue">issue shares</font> of <font color="blue">preferred stock without stockholder approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>preferred <font color="blue">stock could</font> have <font color="blue">voting rights</font>, including <font color="blue">voting rights</font> that could     be superior to that of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, Section 203 of the     <font color="blue">Delaware </font> General  Corporation  Law  contains  provisions  that impose     <font color="blue">restrictions on stockholder action</font> to acquire control of us</td>
    </tr>
    <tr>
      <td>The effect of     these provisions of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue">Delaware </font>law make     it more <font color="blue">difficult</font> to remove <font color="blue">management</font> and <font color="blue">could discourage</font> <font color="blue">third parties</font>     <font color="blue">from seeking</font> to obtain control, even though the <font color="blue">price at which such third</font>     <font color="blue">parties seek</font> to acquire our <font color="blue">common stock</font> is in excess of the <font color="blue">market price</font>     for our stock</td>
    </tr>
  </tbody>
</table>